$9.48 Billion is the total value of Baker Brothers Advisors's 134 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 11.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $1,702,933,000 | -19.4% | 23,498,460 | +20.7% | 17.96% | +2.6% |
| SGEN | Buy | Seattle Genetics, Inc. | $1,517,126,000 | -9.4% | 43,235,267 | +15.9% | 16.00% | +15.4% |
| ALXN | Alexion Pharmaceuticals, Inc. | $910,861,000 | -27.0% | 6,542,599 | 0.0% | 9.61% | -7.1% | |
| ABBV | AbbVie Inc. | $821,016,000 | -3.6% | 14,373,538 | 0.0% | 8.66% | +22.8% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $677,019,000 | -7.3% | 24,213,838 | +18.2% | 7.14% | +18.0% |
| Incyte Corporation Notes 1.25% 11/15/2020 144Anote 1.25% 11/15/2020 | $432,150,000 | -27.6% | 274,500,000 | 0.0% | 4.56% | -7.8% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Anote 0.375% 11/15/2018 | $397,943,000 | -28.5% | 259,000,000 | 0.0% | 4.20% | -9.0% | ||
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $396,439,000 | -8.0% | 4,806,483 | +16.8% | 4.18% | +17.1% |
| GHDX | Buy | Genomic Health, Inc. | $338,354,000 | -29.6% | 13,659,832 | +0.0% | 3.57% | -10.4% |
| ANAC | Buy | Anacor Pharmaceuticals, Inc. | $273,791,000 | -42.3% | 5,122,375 | +22.0% | 2.89% | -26.5% |
| DBVT | Buy | DBV Technologies S.A.sponsored adr | $179,336,000 | -9.6% | 5,509,560 | +0.9% | 1.89% | +15.1% |
| ACOR | Buy | Acorda Therapeutics, Inc. | $96,836,000 | -36.8% | 3,661,082 | +2.3% | 1.02% | -19.5% |
| BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017note 1.875% 4/23/2017 | $89,825,000 | -22.0% | 22,379,000 | 0.0% | 0.95% | -0.7% | ||
| Clovis Oncology Inc. 2.5% 9/15/2021note 2.5% 9/15/2021 | $87,801,000 | -20.9% | 129,300,000 | 0.0% | 0.93% | +0.8% | ||
| Gilead Sciences, Inc. 1.625% 5/1/16note 1.625% 5/1/2016 | $85,863,000 | -8.1% | 20,944,000 | 0.0% | 0.91% | +17.1% | ||
| CERS | Cerus Corporation | $80,371,000 | -6.2% | 13,553,275 | 0.0% | 0.85% | +19.4% | |
| Anacor Pharmaceuticals Inc. 2.0% 15 OCT 2021note 2.0% 10/15/2021 | $75,337,000 | -50.5% | 42,000,000 | 0.0% | 0.80% | -37.0% | ||
| New | Xenoport, Inc. Notes 2.5% 2/1/2022note 2.5% 2/1/2022 | $73,436,000 | – | 100,000,000 | +100.0% | 0.77% | – | |
| MRTX | Buy | Mirati Therapeutics, Inc. | $69,947,000 | -25.1% | 3,268,556 | +10.6% | 0.74% | -4.7% |
| Buy | Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021note 1.75% 6/15/2021 | $68,456,000 | +15.4% | 77,083,000 | +49.4% | 0.72% | +47.0% | |
| AQXP | Buy | Aquinox Pharmaceuticals, Inc. | $68,377,000 | -18.8% | 7,752,487 | +14.9% | 0.72% | +3.3% |
| NVTA | Invitae Corporation | $67,057,000 | +24.6% | 6,554,967 | 0.0% | 0.71% | +58.5% | |
| BGNE | New | BeiGene, Ltd.sponsored adr | $56,061,000 | – | 1,912,680 | +100.0% | 0.59% | – |
| HRTX | Heron Therapeutics, Inc. | $55,219,000 | -28.9% | 2,907,784 | 0.0% | 0.58% | -9.5% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $45,494,000 | -53.9% | 4,865,647 | 0.0% | 0.48% | -41.2% | |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $42,480,000 | -71.0% | 15,010,534 | +5.6% | 0.45% | -63.2% |
| IMGN | ImmunoGen, Inc. | $37,935,000 | -37.2% | 4,452,445 | 0.0% | 0.40% | -20.2% | |
| ONCE | Spark Therapeutics, Inc. | $37,253,000 | -34.9% | 1,262,382 | 0.0% | 0.39% | -17.1% | |
| NBIX | Buy | Neurocrine Biosciences, Inc. | $35,414,000 | -26.4% | 895,422 | +5.3% | 0.37% | -6.5% |
| VSAR | Sell | Versartis, Inc. | $25,660,000 | -36.1% | 3,199,559 | -1.3% | 0.27% | -18.6% |
| SGMO | Sangamo BioSciences, Inc. | $24,538,000 | -33.7% | 4,055,876 | 0.0% | 0.26% | -15.6% | |
| AAAP | Buy | Advanced Accelerator Applications S.A.sponsored adr | $21,538,000 | +21.4% | 615,033 | +8.4% | 0.23% | +54.4% |
| Exelixis, Inc. Notes 4.25% 8/15/2019note 4.25% 8/15/2019 | $19,775,000 | -15.0% | 20,000,000 | 0.0% | 0.21% | +8.3% | ||
| ACHN | Buy | Achillion Pharmaceuticals, Inc. | $19,111,000 | -11.4% | 2,475,515 | +23.8% | 0.20% | +12.8% |
| INSM | Buy | Insmed Incorporated | $19,005,000 | +4.7% | 1,500,000 | +50.0% | 0.20% | +33.3% |
| PGNX | Progenics Pharmaceuticals, Inc. | $18,970,000 | -28.9% | 4,350,808 | 0.0% | 0.20% | -9.5% | |
| HALO | Halozyme Therapeutics, Inc. | $18,287,000 | -45.4% | 1,931,057 | 0.0% | 0.19% | -30.3% | |
| TGTX | TG Therapeutics, Inc. | $17,074,000 | -28.6% | 2,003,991 | 0.0% | 0.18% | -9.1% | |
| ITCI | Intra-Cellular Therapies, Inc. | $16,935,000 | -48.3% | 609,166 | 0.0% | 0.18% | -33.9% | |
| XNPT | XenoPort, Inc. | $15,675,000 | -17.9% | 3,475,672 | 0.0% | 0.16% | +4.4% | |
| MDVN | Sell | Medivation, Inc. | $15,168,000 | -52.4% | 329,876 | -50.0% | 0.16% | -39.4% |
| BLUE | Buy | bluebird bio, Inc. | $15,000,000 | +65.5% | 352,943 | +150.1% | 0.16% | +110.7% |
| FOMX | Buy | Foamix Pharmaceuticals Ltd. | $14,616,000 | -12.0% | 2,241,702 | +9.5% | 0.15% | +11.6% |
| BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018note 0.75% 10/15/2018 | $14,125,000 | -10.0% | 12,228,000 | 0.0% | 0.15% | +14.6% | ||
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $13,841,000 | -35.9% | 6,990,189 | +0.1% | 0.15% | -18.4% |
| Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019note 2.0% 8/15/2019 | $13,526,000 | -22.9% | 26,517,000 | 0.0% | 0.14% | -1.4% | ||
| GLPG | Sell | Galapagos NVsponsored adr | $12,688,000 | -45.4% | 303,394 | -17.8% | 0.13% | -30.2% |
| ARRY | Array BioPharma Inc. | $12,716,000 | -30.1% | 4,310,666 | 0.0% | 0.13% | -11.3% | |
| AGIO | Buy | Agios Pharmaceuticals, Inc. | $12,501,000 | +92.6% | 307,915 | +207.9% | 0.13% | +144.4% |
| NVAX | Buy | Novavax, Inc. | $12,277,000 | -33.4% | 2,379,254 | +8.4% | 0.13% | -15.7% |
| Buy | Corsicanto Ltd. 3.5% 1/15/2032note 3.5% 1/15/2032 | $12,103,000 | +170.2% | 15,000,000 | +200.0% | 0.13% | +245.9% | |
| XNCR | Xencor, Inc. | $11,703,000 | -8.2% | 872,072 | 0.0% | 0.12% | +16.0% | |
| DSCI | Derma Sciences, Inc. | $11,632,000 | -32.2% | 3,752,390 | 0.0% | 0.12% | -13.4% | |
| OMER | Buy | Omeros Corporation | $11,493,000 | +117.3% | 749,250 | +122.8% | 0.12% | +175.0% |
| EXEL | New | Exelixis, Inc. | $10,320,000 | – | 2,580,000 | +100.0% | 0.11% | – |
| DMTX | Buy | Dimension Therapeutics, Inc. | $9,802,000 | -29.6% | 1,251,881 | +1.4% | 0.10% | -10.4% |
| GBT | Buy | Global Blood Therapeutics, Inc. | $9,516,000 | -26.4% | 600,000 | +50.0% | 0.10% | -6.5% |
| ASND | Ascendis Pharma A/Ssponsored adr | $9,377,000 | +1.3% | 505,521 | 0.0% | 0.10% | +28.6% | |
| ZGNX | Zogenix, Inc. | $9,240,000 | -37.3% | 1,000,000 | 0.0% | 0.10% | -20.5% | |
| ADHD | Alcobra Ltd. | $8,855,000 | -39.6% | 2,336,359 | 0.0% | 0.09% | -23.8% | |
| ALKS | Alkermes plc | $8,556,000 | -56.9% | 250,251 | 0.0% | 0.09% | -45.5% | |
| LIFE | Sell | aTyr Pharma, Inc. | $8,422,000 | -63.3% | 2,137,606 | -8.5% | 0.09% | -53.2% |
| LGND | Ligand Pharmaceuticals Incorporated | $7,859,000 | -1.2% | 73,386 | 0.0% | 0.08% | +25.8% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $7,844,000 | -43.6% | 123,894 | 0.0% | 0.08% | -27.8% | |
| SAGE | Buy | Sage Therapeutics, Inc. | $7,183,000 | +17.3% | 224,048 | +113.4% | 0.08% | +49.0% |
| MGNX | MacroGenics, Inc. | $6,819,000 | -39.5% | 363,676 | 0.0% | 0.07% | -22.6% | |
| CNCE | Concert Pharmaceuticals, Inc. | $6,774,000 | -28.0% | 495,908 | 0.0% | 0.07% | -9.0% | |
| PRQR | Buy | ProQR Therapeutics N.V. | $6,587,000 | -23.2% | 1,349,719 | +36.6% | 0.07% | -2.8% |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $6,433,000 | -68.3% | 5,498,459 | -33.6% | 0.07% | -59.5% |
| DERM | Dermira, Inc. | $5,687,000 | -40.3% | 275,000 | 0.0% | 0.06% | -24.1% | |
| AKTX | Akari Therapeutics plcsponsored adr | $5,542,000 | -3.4% | 395,882 | 0.0% | 0.06% | +20.8% | |
| LBIO | Sell | Lion Biotechnologies, Inc. | $5,417,000 | -61.4% | 1,066,285 | -41.3% | 0.06% | -50.9% |
| ECYT | Endocyte, Inc. | $5,257,000 | -22.7% | 1,695,865 | 0.0% | 0.06% | -1.8% | |
| ARWR | New | Arrowhead Pharmaceuticals, Inc. | $4,866,000 | – | 1,009,509 | +100.0% | 0.05% | – |
| NTRA | Buy | Natera, Inc. | $4,284,000 | +58.7% | 450,000 | +80.0% | 0.04% | +104.5% |
| VTAE | Buy | Vitae Pharmaceuticals, Inc. | $4,227,000 | +24.5% | 637,597 | +239.9% | 0.04% | +60.7% |
| NeuroDerm Ltd. | $4,307,000 | -17.2% | 305,000 | 0.0% | 0.04% | +4.7% | ||
| RXDX | Ignyta, Inc. | $3,866,000 | -49.5% | 571,000 | 0.0% | 0.04% | -34.9% | |
| LOXO | Loxo Oncology, Inc. | $3,766,000 | -3.9% | 137,735 | 0.0% | 0.04% | +25.0% | |
| TRVN | Trevena, Inc. | $3,722,000 | -21.2% | 450,000 | 0.0% | 0.04% | 0.0% | |
| AERI | Aerie Pharmaceuticals, Inc. | $3,640,000 | -50.1% | 299,356 | 0.0% | 0.04% | -36.7% | |
| AIMT | Aimmune Therapeutics, Inc. | $3,390,000 | -26.5% | 250,000 | 0.0% | 0.04% | -5.3% | |
| MDGN | Medgenics Inc. | $3,366,000 | -26.9% | 765,000 | 0.0% | 0.04% | -7.9% | |
| MCRB | Seres Therapeutics, Inc. | $3,320,000 | -24.3% | 125,000 | 0.0% | 0.04% | -2.8% | |
| CRIS | Curis, Inc. | $3,219,000 | -44.7% | 1,999,303 | 0.0% | 0.03% | -29.2% | |
| NBRV | Nabriva Therapeutics AGsponsored adr | $3,136,000 | -6.9% | 350,000 | 0.0% | 0.03% | +17.9% | |
| JUNO | Juno Therapeutics, Inc. | $3,047,000 | -13.4% | 80,000 | 0.0% | 0.03% | +10.3% | |
| EPZM | Epizyme, Inc. | $2,818,000 | -24.3% | 232,481 | 0.0% | 0.03% | -3.2% | |
| OSIR | Osiris Therapeutics, Inc. | $2,850,000 | -45.0% | 499,193 | 0.0% | 0.03% | -30.2% | |
| NVIV | New | InVivo Therapeutics Holdings Corp. | $2,792,000 | – | 400,000 | +100.0% | 0.03% | – |
| QURE | Buy | uniQure N.V. | $2,732,000 | +450.8% | 230,000 | +666.7% | 0.03% | +625.0% |
| ADMS | New | Adamas Pharmaceuticals, Inc. | $2,496,000 | – | 172,630 | +100.0% | 0.03% | – |
| Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18note 4.5% 9/15/2018 | $2,334,000 | -1.7% | 3,423,000 | 0.0% | 0.02% | +25.0% | ||
| Array BioPharma Inc. Notes 3.0% 6/1/2020note 3.0% 6/1/2020 | $2,382,000 | -15.4% | 3,000,000 | 0.0% | 0.02% | +8.7% | ||
| SNSS | Sunesis Pharmaceuticals, Inc. | $2,403,000 | -39.8% | 4,450,000 | 0.0% | 0.02% | -24.2% | |
| PRTO | Proteon Therapeutics Inc. | $2,311,000 | -50.1% | 298,591 | 0.0% | 0.02% | -36.8% | |
| IONS | Ionis Pharmaceuticals, Inc. | $2,314,000 | -34.6% | 57,140 | 0.0% | 0.02% | -17.2% | |
| ENTA | Enanta Pharmaceuticals, Inc. | $2,213,000 | -11.1% | 75,357 | 0.0% | 0.02% | +9.5% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $2,082,000 | +16.4% | 711,499 | 0.0% | 0.02% | +46.7% | |
| Trillium Therapeutics Inc. | $1,959,000 | -26.7% | 211,792 | 0.0% | 0.02% | -4.5% | ||
| IRWD | Ironwood Pharmaceuticals, Inc. | $1,851,000 | -5.6% | 169,163 | 0.0% | 0.02% | +25.0% | |
| IMDZ | Immune Design Corp. | $1,936,000 | -35.3% | 148,937 | 0.0% | 0.02% | -20.0% | |
| KPTI | Karyopharm Therapeutics Inc. | $1,936,000 | -32.7% | 216,990 | 0.0% | 0.02% | -16.7% | |
| CYTR | CytRx Corporation | $1,769,000 | +1.1% | 659,995 | 0.0% | 0.02% | +35.7% | |
| MDWD | Buy | MediWound Ltd. | $1,824,000 | -5.1% | 226,000 | +0.4% | 0.02% | +18.8% |
| AFMD | Affimed N.V. | $1,496,000 | -47.5% | 400,000 | 0.0% | 0.02% | -33.3% | |
| OPHT | Ophthotech Corporation | $1,507,000 | -46.2% | 35,649 | 0.0% | 0.02% | -30.4% | |
| STML | Stemline Therapeutics, Inc. | $1,554,000 | -26.1% | 333,497 | 0.0% | 0.02% | -5.9% | |
| DVAX | Dynavax Technologies Corporation | $1,443,000 | -20.4% | 75,000 | 0.0% | 0.02% | 0.0% | |
| CLLS | Cellectis S.A.sponsored ads | $1,375,000 | -11.4% | 50,000 | 0.0% | 0.02% | +15.4% | |
| MSTX | Mast Therapeutics, Inc. | $1,309,000 | -35.1% | 4,797,442 | 0.0% | 0.01% | -17.6% | |
| DNAI | ProNai Therapeutics, Inc. | $1,348,000 | -55.2% | 200,000 | 0.0% | 0.01% | -44.0% | |
| ASMB | Assembly Biosciences, Inc. | $1,255,000 | -33.2% | 250,000 | 0.0% | 0.01% | -18.8% | |
| AMRN | Sell | Amarin Corporation plcsponsored adr new | $1,227,000 | -70.6% | 801,860 | -63.6% | 0.01% | -62.9% |
| PTN | Palatin Technologies, Inc. | $1,107,000 | -18.7% | 2,050,000 | 0.0% | 0.01% | +9.1% | |
| GWPH | New | GW Pharmaceuticals plcads | $1,082,000 | – | 15,000 | +100.0% | 0.01% | – |
| TENX | Tenax Therapeutics, Inc. | $861,000 | -37.5% | 420,000 | 0.0% | 0.01% | -18.2% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $813,000 | -32.6% | 100,000 | 0.0% | 0.01% | -10.0% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $712,000 | -33.3% | 11,340 | 0.0% | 0.01% | -11.1% | |
| ABUS | Arbutus Biopharma Corporation | $746,000 | -7.2% | 180,582 | 0.0% | 0.01% | +14.3% | |
| FPRX | Five Prime Therapeutics, Inc. | $782,000 | -2.1% | 19,247 | 0.0% | 0.01% | +14.3% | |
| XLRN | Acceleron Pharma, Inc. | $759,000 | -45.9% | 28,765 | 0.0% | 0.01% | -33.3% | |
| BDSI | BioDelivery Sciences International, Inc. | $678,000 | -32.6% | 210,021 | 0.0% | 0.01% | -12.5% | |
| CMRX | Chimerix, Inc. | $589,000 | -42.9% | 115,216 | 0.0% | 0.01% | -33.3% | |
| ALDX | Aldeyra Therapeutics, Inc. | $595,000 | -38.2% | 142,000 | 0.0% | 0.01% | -25.0% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $452,000 | -33.5% | 400,000 | 0.0% | 0.01% | -16.7% | |
| DSCO | New | Discovery Laboratories, Inc. | $426,000 | – | 254,973 | +100.0% | 0.00% | – |
| FMI | Foundation Medicine, Inc. | $380,000 | -13.6% | 20,892 | 0.0% | 0.00% | 0.0% | |
| LJPC | La Jolla Pharmaceutical Company | $287,000 | -22.6% | 13,746 | 0.0% | 0.00% | 0.0% | |
| AKAOQ | Achaogen, Inc. | $276,000 | -51.9% | 100,000 | 0.0% | 0.00% | -40.0% | |
| Aptose Biosciences Inc. | $100,000 | +19.0% | 33,397 | 0.0% | 0.00% | 0.0% | ||
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $76,000 | +46.2% | 13,253 | 0.0% | 0.00% | – | |
| CCXI | ChemoCentryx, Inc. | $122,000 | -69.3% | 49,064 | 0.0% | 0.00% | -66.7% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $12,000 | -50.0% | 20,084 | 0.0% | 0.00% | – | |
| DSCO | Exit | Discovery Laboratories, Inc. | $0 | – | -3,569,643 | -100.0% | -0.01% | – |
| MRNS | Exit | Marinus Pharmaceuticals, Inc. | $0 | – | -200,000 | -100.0% | -0.01% | – |
| OHRP | Exit | Ohr Pharmaceuticals, Inc. | $0 | – | -370,370 | -100.0% | -0.02% | – |
| FLXN | Exit | Flexion Therapeutics, Inc. | $0 | – | -146,642 | -100.0% | -0.02% | – |
| ARWR | Exit | Arrowhead Research Corp. | $0 | – | -1,009,509 | -100.0% | -0.05% | – |
| GILD | Exit | Gilead Sciences, Inc. | $0 | – | -249,995 | -100.0% | -0.21% | – |
| DYAX | Exit | Dyax Corp. | $0 | – | -8,310,017 | -100.0% | -2.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-16
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.